Market Exclusive

Analyst Activity – Cowen and Company Initiates Coverage On Alder BioPharmaceuticals (NASDAQ:ALDR) With a Outperform

Analyst Ratings For Alder BioPharmaceuticals (NASDAQ:ALDR)

Today, Cowen and Company initiated coverage on Alder BioPharmaceuticals (NASDAQ:ALDR) with a Outperform.

There are 1 hold rating, 10 buy ratings on the stock.

The current consensus rating on Alder BioPharmaceuticals (NASDAQ:ALDR) is Buy (Score: 2.91) with a consensus target price of $33.82 per share, a potential 211.69% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Alder BioPharmaceuticals (NASDAQ:ALDR)
Alder BioPharmaceuticals (NASDAQ:ALDR) has insider ownership of 10.60% and institutional ownership of 76.16%.

Recent Trading Activity for Alder BioPharmaceuticals (NASDAQ:ALDR)
Shares of Alder BioPharmaceuticals closed the previous trading session at with shares trading hands.

Exit mobile version